Sodium ‐glucose Cotransporter 2 Inhibitors‐ a Drug with Anti‐diabetic and Cardioprotective Properties
AbstractRecently, two large double ‐blind randomized controlled trials testing the effect of sodium‐glucose cotransporter 2 (SGLT2) inhibitors in patients with heart failure with and without diabetes have led to a paradigm shift for the indication of this class of drugs. Key clinical features and main results in these two studies are summarized in Table 1 and 2. The dapagliflozin and prevention of adverse outcomes in heart failure (DAPA‐HF) trial included 4744 patients with heart failure and a reduced ejection fraction (HFrEF).
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Hung ‐Yuan Li Tags: COMMENTARY Source Type: research
More News: Cardiology | Dapagliflozin | Diabetes | Endocrinology | Forxiga | Heart | Heart Failure | SGLT2 Inhibitors | Sodium | Study